Dynamic hepatic recycling glucose tolerance test

• US 20050238581A1
• Filed: 02/16/2005
• Published: 10/27/2005
• Est. Priority Date: 08/16/2002
• Status: Abandoned Application

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Xu, Jun, Kurland, Irwin J., Saad, Mohammed, Lee, W. N. Paul
• Application Number:
  US11/060,640
• Publication Number:
  US 20050238581A1
• Time in Patent Office: Days
• US Class Current: 424/9.200
• CPC Class Codes: A61B 1/00 Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes examination of body cavities or body tracts using ultrasonic, sonic or infrasonic waves A61B8/12; endoscopic instruments for taking cell samples or for biopsy A61B10/04; for surgical purposes A61B17/00; endoscopic surgical cutting instruments A61B17/32; surgical instruments using a laser beam being directed along or through a flexible conduit A61B18/22; Illuminating arrangements therefor for the eyes A61B3/00
• CPC Class Codes: A61K 49/00 Preparations for testing in vivo
• CPC Class Codes: C12Q 1/54 involving glucose or galactose
• CPC Class Codes: G01N 2800/042 Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
• CPC Class Codes: G01N 33/00 Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
• CPC Class Codes: G01N 33/53 Immunoassay; Biospecific binding assay; Materials therefor
• CPC Class Codes: G01N 33/564 for pre-existing immune complex or autoimmune disease , i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
• CPC Class Codes: G01N 37/00 Details not covered by any other group of this subclass

Abstract

Systems and methods are described providing a hepatic recycling glucose tolerance test for the diagnosis of types and subtypes of diabetes mellitus and other hyperglycemic or hypoglycemic conditions. A method is also provided for screening candidate drugs for treating various types of abnormal glucose metabolism and to monitor whether the course of treatment is effective. The method also allows the correlation of gene activity, hormone and metabolite levels with glucose flux and recycling and an assessment of the degree of hepatic insulin resistance. The method utilizes a preferably non-radioactive stable labeled glucose to asses the relative rates of carbon flow in the liver and provides a hepatic recycling constant that is a measure of the relative rate of glucose recycling. The labeled glucose may be introduced to the patient orally, intravenously or by intraperitoneal administration for the desired effect.

Claims

1. A method for diagnosing diabetes mellitus, comprising:

administering a plurality of labeled glucose molecules to a patient;

quantifying the glucose flux and glucose recycling over time after said administration of labeled glucose; and

comparing quantified glucose flux and recycling with a standard to assess the status of the health of the patient.

2. A method as recited in claim 1, further comprising:

measuring insulin levels at time points after said administration of labeled glucose to said patient; and

correlating said insulin levels with said quantified glucose flux and glucose recycling.

3. A method as recited in claim 1, wherein said labeling comprises:

labeling a first carbon of said glucose at a first end of said glucose molecule; and

labeling a second carbon in said glucose molecule.

4. A method as recited in claim 3, wherein said labeled first carbon is the first carbon to be metabolized during glucose metabolism.

5. A method as recited in claim 1, wherein said label comprises a non-radioactive isotope of carbon.

6. A method as recited in claim 5, wherein said non-radioactive isotope of carbon label comprises a ¹³C isotope.

7. A method as recited in claim 3, wherein said first carbon is labeled with a non-radioactive isotope of carbon and said second carbon is labeled with a non-radioactive isotope of carbon.

8. A method as recited in claim 7, wherein said non-radioactive isotope of carbon label comprises a ¹³C isotope.

9. A method as recited in claim 3, wherein said first carbon is labeled with a non-radioactive isotope of carbon and said second carbon is labeled with a deuterium marker.

10. A method as recited in claim 3, wherein said first carbon is labeled with a deuterium marker and said second carbon is labeled with a deuterium marker.

11. A method for diagnosing diabetes mellitus, comprising:

administering a plurality of labeled glucose molecules to a patient;

quantifying the glucose flux and glucose recycling over time after said administration of labeled glucose;

comparing quantified glucose flux and recycling with a standard to assess the status of the health of the patient;

measuring insulin levels at time points after said administration of labeled glucose to said patient; and

correlating said insulin levels with said quantified glucose flux and glucose recycling.

12. A method as recited in claim 11, wherein said labeling comprises:

labeling a first carbon of said glucose at a first end of said glucose molecule; and

labeling a second carbon in said glucose molecule.

13. A method as recited in claim 12, wherein said labeled first carbon is the first carbon to be metabolized during glucose metabolism.

14. A method as recited in claim 11, wherein said label comprises a non-radioactive isotope of carbon.

15. A method as recited in claim 14, wherein said non-radioactive isotope of carbon label comprises a ¹³C isotope.

16. A method as recited in claim 12, wherein said first carbon is labeled with a non-radioactive isotope of carbon and said second carbon is labeled with a non-radioactive isotope of carbon.

17. A method as recited in claim 16, wherein said non-radioactive isotope of carbon label comprises a ¹³C isotope.

18. A method as recited in claim 12, wherein said first carbon is labeled with a non-radioactive isotope of carbon and said second carbon is labeled with a deuterium marker.

19. A method as recited in claim 12, wherein said first carbon is labeled with a deuterium marker and said second carbon is labeled with a deuterium marker.

20. A method for screening drug candidates for biological activity for potential use in treating a hyperglycemic patient, comprising:

labeling at least one carbon atom of a glucose molecule;

introducing labeled glucose molecules into a mammalian test subject;

introducing a candidate drug into said mammalian test subject;

determining the rate of glucose flux through metabolic pathways in the liver and the peripheral muscles; and

comparing determined flux rates with known baseline flux rates in the absence of said candidate drug.

21. A method as recited in claim 20, further comprising:

measuring hormone and metabolite levels of said test subject; and

comparing said measured hormone and metabolite levels with known baseline levels of said hormone and metabolites in the absence of said candidate drug.

22. A method as recited in claim 20, further comprising:

measuring insulin levels at time points after introduction of labeled glucose into said test subject; and

correlating said insulin levels with said rates of glucose flux in the presence of said candidate drug.

23. A method as recited in claim 22, further comprising:

comparing said measured insulin levels with insulin levels observed in the absence of said candidate drug.

24. A method as recited in claim 20, further comprising:

collecting an array of measurements of flux rates, insulin, hormones and metabolite concentrations from a plurality of healthy individuals;

collecting an array of measurements of flux rates, insulin, hormones and metabolite concentrations from a plurality of individuals with diagnosed hyperglycemia; and

comparing said measurements of flux rates, insulin, hormones and metabolite concentrations from said test subject with said array of measurements from healthy individuals and said array of measurements from individuals diagnosed with hyperglycemia.

25. A method as recited in claim 20, wherein said label of said glucose comprises [1, 2-¹³C₂]-glucose.

26. A method as recited in claim 20, further comprising:

monitoring glucose flux and recycling levels at different concentration levels of candidate drug to determine a minimum effective dose of candidate drug.

27. A method as recited in claim 20, further comprising:

determining the rate of glucose recycling through metabolic pathways in the liver and the peripheral tissues.

28. A method for screening drug candidates for biological activity for potential use in treating a hyperglycemic patient, comprising:

labeling at least one carbon atom of a glucose molecule;

introducing labeled glucose molecules into a mammalian test subject;

introducing a candidate drug into said mammalian test subject;

determining the rate of glucose flux through metabolic pathways in the liver and the peripheral muscles;

comparing determined flux rates with known baseline flux rates in the absence of said candidate drug;

measuring hormone and metabolite levels of said test subject; and

comparing said measured hormone and metabolite levels with known baseline levels of said hormone and metabolites in the absence of said candidate drug.

29. A method for screening drug candidates for biological activity for potential use in treating a hyperglycemic patient, comprising:

labeling at least one carbon atom of a glucose molecule;

introducing labeled glucose molecules into a mammalian test subject;

introducing a candidate drug into said mammalian test subject;

determining the rate of glucose flux through metabolic pathways in the liver and the peripheral muscles;

comparing determined flux rates with known baseline flux rates in the absence of said candidate drug;

measuring insulin levels at time points after introduction of labeled glucose into said test subject; and

correlating said insulin levels with said rates of glucose flux in the presence of said candidate drug.

30. A method as recited in claim 29, further comprising:

comparing said measured insulin levels with insulin levels observed in the absence of said candidate drug.

31. A method for screening drug candidates for biological activity for potential use in treating a hyperglycemic patient, comprising:

labeling at least one carbon atom of a glucose molecule;

introducing labeled glucose molecules into a mammalian test subject;

introducing a candidate drug into said mammalian test subject;

determining the rate of glucose flux through metabolic pathways in the liver and the peripheral muscles;

comparing determined flux rates with known baseline flux rates in the absence of said candidate drug;

collecting an array of measurements of flux rates, insulin, hormones and metabolite concentrations from a plurality of healthy individuals;

collecting an array of measurements of flux rates, insulin, hormones and metabolite concentrations from a plurality of individuals with diagnosed hyperglycemia; and

comparing said measurements of flux rates, insulin, hormones and metabolite concentrations from said test subject with said array of measurements from healthy individuals and said array of measurements from individuals diagnosed with hyperglycemia.

32. A method for screening drug candidates for biological activity for potential use in treating a hyperglycemic patient, comprising:

labeling at least one carbon atom of a glucose molecule;

introducing labeled glucose molecules into a mammalian test subject;

introducing a candidate drug into said mammalian test subject;

determining the rate of glucose flux through metabolic pathways in the liver and the peripheral muscles; and

comparing determined flux rates with known baseline flux rates in the absence of said candidate drug;

wherein said label of said glucose comprises [1, 2-¹³C₂]-glucose.

33. A method for screening drug candidates for biological activity for potential use in treating a hyperglycemic patient, comprising:

labeling at least one carbon atom of a glucose molecule;

introducing labeled glucose molecules into a mammalian test subject;

introducing a candidate drug into said mammalian test subject;

determining the rate of glucose flux through metabolic pathways in the liver and the peripheral muscles;

comparing determined flux rates with known baseline flux rates in the absence of said candidate drug; and

monitoring glucose flux and recycling levels at different concentration levels of candidate drug to determine a minimum effective dose of candidate drug.

34. A method for screening drug candidates for biological activity for potential use in treating a hyperglycemic patient, comprising:

labeling at least one carbon atom of a glucose molecule;

introducing labeled glucose molecules into a mammalian test subject;

introducing a candidate drug into said mammalian test subject;

determining the rate of glucose flux through metabolic pathways in the liver and the peripheral muscles;

comparing determined flux rates with known baseline flux rates in the absence of said candidate drug; and

determining the rate of glucose recycling through metabolic pathways in the liver and the peripheral tissues.